A PARP Inhibitor for Ovarian Cancer | NEJM
Quick Take Video Summary from The New England Journal of Medicine — A PARP Inhibitor for Ovarian Cancer
Related Articles
Childhood Obesity and GLP-1 Receptor Agonists — A Coming of Age? | NEJM
Childhood obesity, defined as an age-adjusted and sex-adjusted body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) in…
Liraglutide for Children 6 to <12 Years of Age with Obesity — A Randomized Trial | NEJM
No medications are currently approved for the treatment of nonmonogenic, nonsyndromic obesity in children younger than 12 years of age. Although the use of liraglutide…
“Do You Feel Safe at Home?” | NEJM
When a patient takes offense at her questions about possible intimate partner violence, a physician convinces herself she must set aside her intuitions to retain…
Interview with Erin Fuse Brown on the potential implications of recent Supreme Court decisions for health law and policy. | NEJM
Audio Interview from the New England Journal of Medicine — Interview with Erin Fuse Brown on the potential implications of recent Supreme Court decisions for…
A New Once-Weekly Insulin — Its Effectiveness and Safety | NEJM
Type 2 diabetes is a common yet complex disorder in which the key hormone for nutrient storage, insulin, is both ineffective and insufficient in most…
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment | NEJM
Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase 1…
Electrocardiographic Findings in Diffuse Subendocardial Ischemia | NEJM
In a 57-year-old man with chest pain, an ECG obtained by EMS showed widespread ST-segment depressions. At the hospital, left main coronary-artery stenosis was seen…
A Monoclonal Antibody to PACAP for Migraine Prevention | NEJM
Targeting pituitary adenylate cyclase–activating polypeptide (PACAP) is a new avenue for treating migraine. The efficacy and safety of intravenous Lu AG09222, a humanized monoclonal antibody…
Making Long-Term Oxygen Therapy Less Burdensome | NEJM
Long-term oxygen therapy, the first intervention that was shown to improve survival in patients with both severe hypoxemia and chronic obstructive pulmonary disease (COPD), had…
Long-Term Oxygen Therapy for 24 or 15 Hours per Day in Severe Hypoxemia | NEJM
Long-term oxygen supplementation for at least 15 hours per day prolongs survival among patients with severe hypoxemia. On the basis of a nonrandomized comparison, long-term…